Ronald Gentile, M.D.
To establish the safety and efficacy of Vitrenase when given as intravitreous injection after vitrectomy in patients with PVR and retinal detachment.
One hundred fifty-four patients completed the study. Forty-one patients (27%) developed recurrent retinal detachment due to PVR by 24 weeks, including 18 patients (33%) in the group receiving 0.75 mg, 13 patients (24%) in the group receiving 0.15 mg, and 10 patients (22%) in the placebo group. There was no statistically significant difference in patients reaching this end point by 24 weeks (P = .37). Ancillary statistical analyses are reported.
VIT100 was not effective in preventing PVR recurrence in patients with established grade C or worse PVR
For more information: